Session » Pediatric Rheumatology – Clinical Poster I

Date: Saturday, November 16, 2024

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2024

10:30AM-12:30PM: Abstract Number: 0387

Absolute Agreement and Inter-rater Reliability of a Web-based Standardized Scoring Tool for Magnetic Resonance Images from Children with Chronic Nonbacterial Osteomyelitis (CNO) Amongst Radiologists

10:30AM-12:30PM: Abstract Number: 0408

Analysis of Protein Biomarkers for the Prediction of IL-1 Inhibitor Treatment Response in the CARRA First-line Options for Systemic Juvenile Idiopathic Arthritis Treatment (FROST) Study

10:30AM-12:30PM: Abstract Number: 0395

Assessment of Enthesitis by Pediatric Rheumatology Providers

10:30AM-12:30PM: Abstract Number: 0411

Axial Radiographic Structural Damage in Enthesitis-Related Arthritis in Children and Young Adult Patients

10:30AM-12:30PM: Abstract Number: 0401

Biologic Abatement and Capturing Kids Outcomes and Flare Frequency in Juvenile Spondyloarthritis: Baseline Characteristics and Enrollment

10:30AM-12:30PM: Abstract Number: 0382

Comparative Analysis of Tear-based S100 Proteins, Cytokines, and Chemokines Levels in Juvenile Idiopathic Arthritis Associated-uveitis: Insights into Eye Laterality and Severity of Ocular Inflammation

10:30AM-12:30PM: Abstract Number: 0403

Comparing Domains Reported by Patients and Other Collaborators in CNO and SAPHO: A Qualitative Study and Scoping Review Using the OMERACT Process

10:30AM-12:30PM: Abstract Number: 0385

Cross-cultural Validation of the “Effects of Youngsters-Eyesight on Quality of Life (EYE-Q)”: A Measure of Vision-related Quality of Life and Function in Childhood Uveitis

10:30AM-12:30PM: Abstract Number: 0406

Delayed Diagnosis and Accrual of Joint Damage in Incident Cases of Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 0409

Differences in Clinical Presentation and Outcomes Between Down Syndrome-Associated Arthritis and Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 0378

Disparate Disease Activity Outcomes Associated with Demographic Variables in Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network Registry

10:30AM-12:30PM: Abstract Number: 0379

Effectiveness and Safety of Baricitinib for the Treatment of Juvenile Idiopathic Arthritis Associated Uveitis or Chronic Anterior Antinuclear Antibody Positive Uveitis in Children

10:30AM-12:30PM: Abstract Number: 0393

Effectiveness of Secukinumab in TMJ Symptoms in Children with JPsA and ERA: A Secondary Data Analysis of JUNIPERA

10:30AM-12:30PM: Abstract Number: 0413

Efficacy of Intra-articular Glucocorticoids as a Treatment for Oligoarticular Juvenile Idiopathic Arthritis: A Bicentric Retrospective Study in Japan

10:30AM-12:30PM: Abstract Number: 0410

Efficacy of Modified Dosing/interval Timing of Adalimumab in Patients Affected by Chronic Non Infectious Uveitis: A Retrospective Monocentric Study

10:30AM-12:30PM: Abstract Number: 0399

Eosinophilia and Exposure to IL-1 and IL-6 Blocking Biologic Medications in a Systemic Juvenile Idiopathic Arthritis Patient Cohort

10:30AM-12:30PM: Abstract Number: 0392

Evaluation for the Presence of Antibodies to Malondialdehyde-Acetaldehyde Adduct in Juvenile Idiopathic Arthritis and Its Subtypes

10:30AM-12:30PM: Abstract Number: 0389

Histopathological Features of Liver Tissue Biopsies in SJIA Patients with and Without Clinical Macrophage Activation Syndrome

10:30AM-12:30PM: Abstract Number: 0383

Identification of Protein Biomarkers in Tear Fluid of Children with Uveitis That Distinguishes the Ocular Inflammatory State

10:30AM-12:30PM: Abstract Number: 0412

Impact of Approval of Biologic DMARDs on JIA Outcomes in a Single Center

10:30AM-12:30PM: Abstract Number: 0377

Improving Self-Management Support in Patients with Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 0396

Inflammatory Markers of Autoimmune Uveitis in the Eye, Tears and Blood

10:30AM-12:30PM: Abstract Number: 0380

Joint Acoustic Emissions as a Digital Biomarker for Knee Inflammation in Juvenile Idiopathic Arthritis: A Pilot Study Using Musculoskeletal Ultrasound as Ground Truth

10:30AM-12:30PM: Abstract Number: 0404

Methotrexate Adherence in JIA: Use of Electronic Health Record-Linked Pharmacy DispensingData

10:30AM-12:30PM: Abstract Number: 0405

Olokizumab, a Monoclonal Antibody Against IL-6, in Polyarticular-course Juvenile Idiopathic Arthritis (pcJIA): Results of 24 Weeks of the Phase 2 Open-label Clinical Trial

10:30AM-12:30PM: Abstract Number: 0400

Osteoclastogenesis from Peripheral Blood Mononuclear Cells in Children with Chronic Nonbacterial Osteomyelitis Are Similar to Those from Healthy Children

10:30AM-12:30PM: Abstract Number: 0384

Pharmacokinetics of Ustekinumab in Patients with Juvenile Psoriatic Arthritis in a Real‑World Opportunistic Study

10:30AM-12:30PM: Abstract Number: 0376

Preliminary Results of the Ondansetron Pre-medication Trial in Juvenile Idiopathic Arthritis: A Pragmatic Randomized Controlled Trial Nested in the CAPRI Registry

10:30AM-12:30PM: Abstract Number: 0415

Prevalence and Risk Factors of Low Bone Mineral Density in Children with Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 0407

Prevalence of Autoimmune Diseases in 8244 Family Members of Children with Juvenile Idiopathic Arthritis: A Study from India

10:30AM-12:30PM: Abstract Number: 0416

Proteomic Signatures of Synovial Fluid in Different Subtypes of Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 0414

Relationship Between Culture Negative Infectious Osteomyelitis and Chronic Nonbacterial Osteomyelitis

10:30AM-12:30PM: Abstract Number: 0402

Reporting of Clinical Features and Outcome Measures in Still’s Disease: A Systematic Literature Review of sJIA and AOSD Cohorts

10:30AM-12:30PM: Abstract Number: 0388

The Association Between Body Composition and Disease and Treatment Outcomes in Patients with Juvenile Idiopathic Arthritis: Results from the CAPRI Registry

10:30AM-12:30PM: Abstract Number: 0390

Treatment Effectiveness Following Switching from Initial TNF Inhibitor in Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 0397

Trends in New Use of Disease-Modifying Antirheumatic Drugs in Juvenile Idiopathic Arthritis Among Commercially Insured Children in the United States from 2001-2022

10:30AM-12:30PM: Abstract Number: 0381

Two- and 3-Year Outcomes of the Childhood Arthritis and Rheumatology Research Alliance FROST Study of New-onset Systemic JIA Treatment

10:30AM-12:30PM: Abstract Number: 0394

Unveiling Major Challenges and Unmet Needs in the Therapeutic Approach to Systemic Juvenile Idiopathic Arthritis: The Patient Perspective

10:30AM-12:30PM: Abstract Number: 0391

Using Machine Learning to Predict Inactive Disease in Juvenile Idiopathic Arthritis

10:30AM-12:30PM: Abstract Number: 0398

Validation of Patient-Reported Outcomes Measurement Information System® (PROMIS®) Pediatric Measures for Children with Chronic Nonbacterial Osteomyelitis Using the CHOIR Data

10:30AM-12:30PM: Abstract Number: 0386

Variability of Data Completeness and Consensus Treatment Plan Adherence for Polyarticular Juvenile Idiopathic Arthritis Patients Within the Childhood Arthritis and Rheumatology Research Alliance Registry

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].